

1 ***Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2***  
2 ***strain [D614G] in an outpatient household cohort***

3  
4 **Short Title** Symptom burden, viral load, and antibody response to ancestral COVID-19

5  
6 Mehal Churiwal<sup>1</sup>, Kathleen Tompkins<sup>1</sup>, Gabrielle Streeter<sup>1</sup>, Christy Litel<sup>1</sup>, Sydney Mason<sup>1</sup>, Kelly Lin<sup>1</sup>,  
7 Meredith Muller<sup>1</sup>, Srijana Chhetri<sup>1</sup>, Tia Belvin<sup>1</sup>, Christopher Basham<sup>1</sup>, Maureen Whittelsey<sup>1</sup>, Tyler Rapp<sup>1</sup>,  
8 Lakshmanane Premkumar<sup>2</sup>, Carla Cerami<sup>3</sup>, Jessica T. Lin<sup>1,2\*</sup>

9  
10 **1** Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel  
11 Hill, NC USA

12 **2** Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill,  
13 NC USA

14 **3** Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, The  
15 Gambia.

16  
17 \*Corresponding author

## 19 Abstract

20 **Background** Early in the SARS-CoV-2 pandemic, description of COVID-19 illness among non-hospitalized  
21 patients was limited. Data from household cohorts can help reveal the full spectrum of disease and the  
22 potential for long-term sequelae, even in non-severe disease.

23  
24 **Methods** Daily symptom diaries were collected in a US household cohort of SARS-CoV-2 infection from  
25 April to November 2020, during the pre-COVID vaccine period. SARS-CoV-2 nasal viral loads were  
26 measured at study entry and weekly until day 21; serologic testing was performed at study entry and day  
27 28. A subset of volunteers underwent an additional assessment 8-10 months later. Participants who met  
28 the criteria for early infection—testing antibody-negative at study entry but PCR-positive either at  
29 baseline or during follow-up—were included in this analysis (n=143).

30  
31 **Results** Daily symptoms were ascertained in 143 outpatients with acute COVID-19, including 60 index  
32 cases who sought testing and 83 of their household contacts. Asymptomatic cases comprised 16%  
33 (13/83) of SARS-CoV-2 infections detected among household contacts. Among 119 persons with mild or  
34 moderate illness, the number of symptoms peaked 3 or 4 days after symptom onset. Fever and anosmia  
35 occurred in nearly half of participants. Symptom severity was associated with increased age, viral load,  
36 and cardiovascular disease. Increased BMI was associated with a higher antibody level at day 28,  
37 independent of symptom severity. Those with a higher day 28 antibody level were more likely to develop  
38 symptoms consistent with post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID-19, 8-10  
39 months later.

40  
41 **Conclusions** Fever, anosmia, as well as asymptomatic infection were common features of COVID-19 non-  
42 severe illness when the D614G variant circulated in the US, before the availability of vaccines or  
43 outpatient therapies. Antibody levels following acute infection were linked to the development of  
44 symptoms of PASC 8-10 months later.

## 46 Introduction

47 At the onset of the COVID-19 pandemic in 2019-2020, research on its clinical course, viral load, and  
48 antibody responses to SARS-CoV-2 largely focused on patients who presented to or were admitted to  
49 hospitals and medical centers [1–3]. Since an estimated 81% of infections caused no or mild pneumonia  
50 [4], these descriptions were limited in their ability to describe the full spectrum of disease. Detailed

51 descriptions of symptom spectrum and severity are needed to best understand whether clinical patterns  
52 of disease are changing as the virus evolves and new variants emerge. They are also useful for  
53 determining who may be at risk for post-acute sequelae of SARS-CoV-2 infection (PASC) given the large  
54 number of persons contracting non-severe disease throughout the pandemic.

55  
56 Household cohorts, in which family members (household contacts) are followed after an index case is  
57 diagnosed with SARS-CoV-2 infection, provide the ideal study design for capturing acute infection in  
58 secondary cases that better reflect the full spectrum of disease. The UNC CO-HOST Study (COVID-19  
59 Household Transmission Study) was an observational cohort study involving approximately 100  
60 households across a diverse socio-demographic cohort in central North Carolina with the primary aim of  
61 determining secondary household attack rates in households where infected individuals self-isolated at  
62 home [5]. Here, we report the results from individuals with SARS-CoV-2 infection and their PCR-positive  
63 household contacts who tested positive over the course of the study. We describe the course of  
64 symptoms, quantitative nasal viral loads, and antibody responses over a 28-day period. We additionally  
65 evaluated vaccination status, post-acute sequelae, and antibody titers in a subset of participants 8-10  
66 months after acute infection.

## 67 68 **Methods**

### 69 **Study design and sample collection**

70 Details of the UNC CO-HOST study have been described previously [5]. Briefly, between 28/04/2020  
71 and 20/11/2020, participants were enrolled in a prospective longitudinal cohort study. Index cases were  
72 enrolled through a COVID-19 testing center at the University of North Carolina at Chapel Hill that  
73 provided PCR results within 24 hours, allowing for timely study enrollment. Index cases were eligible for  
74 enrollment if they were at least 18 years of age, had a positive COVID-19 PCR test at the testing center,  
75 and lived within a 1-hour driving distance of the university. Household contacts at least 1 year of age  
76 living in the same home as the index patient were invited to enroll if they intended to remain in the home  
77 for the 28-day study period. Pre-screening was conducted via phone, and enrollment and study visits  
78 were conducted outside participants' homes using a mobile medical van.

79  
80 Incident SARS-CoV-2 infection in the household was detected based on PCR testing at baseline and  
81 weekly PCR thereafter until study day 21, as well as serologic testing at study entry and 28 days later. At  
82 study entry, all study participants received nasopharyngeal (NP) and nasal mid-turbinate (NMT) swabs

83 for PCR testing, with instructions on how to self-perform NMT swabs for future visits. Quantitative PCR  
84 testing was performed using a CDC RT-qPCR protocol authorized for emergency use [6]. NP viral loads  
85 were mathematically transformed into corresponding NMT viral load values based on data from paired  
86 samples [7]. At study entry, participants also had venipuncture for serology testing by enzyme-linked  
87 Immunosorbent Assay (ELISA) and a finger stick for rapid point-of-care lateral flow assay antibody  
88 testing (Biomedomics, Morrisville, NC). ELISA testing was performed using an in-house assay targeting  
89 the SARS-CoV-2 receptor binding domain [8]. On days 7, 14, and 21 of the study, participants performed  
90 self-collected NMT swabs for viral load PCR testing. On day 28 of the study, participants underwent  
91 repeat blood collection for serology by ELISA. All samples were immediately placed on ice and  
92 transferred to a BSL-2 laboratory for processing within 2 hours.

### 94 **Symptom evaluation**

95 Participants completed a baseline questionnaire that included an assessment of symptoms, and they  
96 subsequently completed electronic daily symptom diaries that were sent via email. In the baseline  
97 questionnaire, participants were asked to quantify the number of days symptoms were present for any  
98 symptom reported. Symptom diaries consisted of a checklist of 14 symptoms in both English and Spanish  
99 that the participant completed if they answered “Yes” to the question “Are you having any symptoms?”  
100 These 14 symptoms were: fever, chills, muscle aches, runny nose, sore throat, loss of taste or smell,  
101 cough, shortness of breath, chest pain, wheezing, diarrhea, vomiting/nausea, headache, and abdominal  
102 pain.

103  
104 Index cases completed daily symptom diaries until no symptoms were reported for two consecutive days.  
105 Household contacts received daily symptom evaluations until study day 21 to evaluate for symptoms that  
106 could be consistent with new infection. If a participant failed to fill out a symptom diary for two  
107 consecutive days, they were contacted by study staff to facilitate completion. Symptom evaluation was  
108 performed over the phone for participants who indicated this preference. Questionnaires and symptom  
109 diaries for minors were sent to and completed by their designated guardians if no separate email for the  
110 minor was provided. If a participant was hospitalized, they remained in the study for outcome  
111 assessment, but no further samples or questionnaires were collected/sent.

### 113 **Extended follow up**

114 Participants were re-contacted between 8-10 months after their initial enrollment, between 05/05/2021  
115 and 27/08/2021, for a voluntary follow-up assessment. This consisted of a single visit during which they  
116 completed a questionnaire on their current state of health, persistence of 10 symptoms potentially  
117 attributable to post-acute sequelae of SARS-CoV-2 infection (PASC or “long COVID”), additional  
118 documented COVID-19 infections, and receipt of the COVID-19 vaccine. Additionally, they reported their  
119 current state of health, additional documented COVID-19 infections, and receipt of the COVID-19 vaccine.  
120 They also had venipuncture for ELISA antibody testing.

## 122 **Ethics, standards, and informed consent**

123 The study was approved by the Institutional Review Board at the University of North Carolina and is  
124 registered at [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04445233). All participants (or their parents/guardians) gave  
125 written, informed consent. Minors over the age of 7 provided assent.

## 127 **Statistical analysis**

128 The results presented here detail the reported symptoms, viral loads, and antibody responses of  
129 participants who tested positive for SARS-CoV-2 immediately prior to study entry or during the 28-day  
130 duration of the study. We considered individuals to be recently or newly infected if they had a positive  
131 viral load on any nasal swab and were antibody-negative at study entry, or if they seroconverted during  
132 the course of the study. Individuals who were seropositive by either ELISA or rapid antibody testing at  
133 study entry were excluded from analysis as they may represent prior infections or late enrollment of a  
134 primary infection and thus may have been past their symptom and viral load peaks.

136 Data were collected into a RedCap database (Vanderbilt University) and analyzed using STATA software  
137 (College Station, TX) and R 4.0.2 (R Core Team, Vienna, Austria). Day of symptom onset in relation to  
138 study entry was based on either a survey administered by the UNC diagnostic center regarding symptom  
139 duration for each symptom endorsed or a similar question in the baseline questionnaire (whichever was  
140 earliest); for incident cases in the household, day of symptom onset was captured in real-time through  
141 the daily symptom diaries.

143 Participants were categorized as being asymptomatic, or having mild, moderate, or severe/hospitalized  
144 symptoms based on a modified CDC definition [9]. Symptoms were quantified cumulatively throughout  
145 the study to capture both the number of symptoms per day and the duration of symptoms. For example, if

146 an individual reported 1 symptom on day 1, 3 symptoms on day 2, and 1 symptom on day 3, they would  
147 be considered to have 5 cumulative symptoms. Participants were considered asymptomatic if they  
148 reported at most 1 cumulative symptom for the duration of their enrollment. Additionally, the symptom  
149 reported could not be anosmia, dyspnea, or new or worsening cough. Participants were considered to  
150 have mild illness if they reported between 2 and 10 cumulative symptoms or 1 symptom of anosmia,  
151 dyspnea, or new or worsening cough. Participants were considered to have moderate illness if they  
152 reported 11 or more cumulative symptoms but were not hospitalized and severe illness if they were  
153 hospitalized or died during the study. Since symptom diaries were not collected once a participant was  
154 hospitalized, 10 symptoms for each day of hospitalization were imputed for study analyses. The number  
155 of cumulative symptoms on any given day starting from the day of onset was plotted to depict the pattern  
156 of illness in those with different disease severity. Calculations were only done on true reported data. On  
157 days when symptom diaries were not filled out, the data was treated as null, and the other complete  
158 symptom diaries were used to inform calculations. Overall, there was <10% missing data from symptom  
159 diaries.

160  
161 We examined the frequency and duration of twelve commonly reported symptoms. Associations between  
162 symptom severity and participant characteristics were calculated using one-way ANOVA or chi-squared  
163 testing. Associations between viral load (highest viral load measured, usually on day of enrollment for  
164 index cases), antibody responses, and patient characteristics were calculated using simple linear  
165 regression or one-way ANOVA. Associations between the presence of PASC symptoms, antibody status,  
166 and patient characteristics were assessed using Mann-Whitney U or chi-squared testing. All COVID-  
167 positive individuals from the original household cohort that were followed up at 8-10 months were  
168 included in the PASC analysis, regardless of whether they were included in the analysis of those with  
169 acute infection.

## 171 **Results**

### 172 **Symptom severity**

173 Between April 28 and November 20, 2020, 315 individuals from 102 households were enrolled in the  
174 UNC CO-HOST Study. Of these, 143 individuals met our criteria for early SARS-CoV-2 infection (PCR-  
175 positive and antibody-negative at study entry) and had no more than two days of missing symptom  
176 diaries. This included both 60 index cases who sought testing and 83 of their household contacts, among  
177 which 13/143 (9%) were asymptomatic, 53/143 (37%) had mild illness, 68/143 (48%) had moderate

disease, and 9/143 (6%) were hospitalized (Figure 1). Of the nine who were hospitalized, two ultimately died. Asymptomatic infections comprised 16% (13/83) of household contacts diagnosed by active surveillance. Secondary infections detected in household contacts had fewer cumulative symptoms than index cases who presented to care (cumulative 9.7 vs. 16.4 symptoms, respectively,  $p < 0.001$ ). Those with mild or moderate illness reported the most symptoms 3 or 4 days after symptom onset, while those with severe disease or who were hospitalized experienced escalating symptoms over more than one week (Figure 1).

### **Fig 1. COVID-19 symptom progression by severity of illness.**

143 study participants that met criteria for newly positive SARS-CoV-2 infection (PCR positive and antibody-negative at study entry) were categorized into symptom severity categories based on the number of cumulative symptoms reported in daily symptom diaries. For the asymptomatic category, days from study enrollment was substituted for days from symptom onset.

### **Frequency, onset, and duration of symptoms**

Participants reported a wide array of symptoms attributable to COVID-19 illness, with more nonspecific symptoms such as cough, headache, and myalgias early in illness and dyspnea and anosmia presenting later in illness. The most frequently reported symptoms were headache (60%), rhinorrhea (57%), and myalgias (55%). Gastrointestinal symptoms were less common, with nausea, abdominal pain, and diarrhea reported by only 19%, 21%, and 24% of participants, respectively (Figure 2A). Fever and anosmia were reported in nearly half the participants (48% and 46%, respectively), with fever usually occurring within the first 3-5 days of illness, while anosmia more commonly presenting later in illness, though usually still within the first week. Fifty-eight (40%) participants reported neither fever nor anosmia. Diarrhea, fever, and nausea had the shortest duration of symptoms, with a mean symptom duration of three days or less. Headache, rhinorrhea, and cough had the longest mean duration of around one week (Figure 2B). Examining only household contacts with COVID-19 illness, youth  $\leq 21$  years ( $N=33$ ) reported lower cumulative symptoms compared to older adults  $>30$  years ( $N=44$ ) (median 6 vs 9 symptoms, respectively;  $p=0.02$ ),

### **Fig 2. Comparison of symptom frequency, onset, and duration.**

The frequency of symptoms depicted according to their timing of onset (A) and total duration (B), with median and interquartile ranges.



## Associations with disease severity

Symptom severity increased with age, cardiovascular disease, and viral load (Table 1). Increasing age correlated with increased symptom severity (mean age of 54 years in those who were hospitalized vs. 31 years in those with asymptomatic and mild disease,  $p=0.003$ ), and the presence of cardiovascular disease (coronary artery disease, hypertension, or diabetes) was associated with severe disease and hospitalization ( $p=0.02$ ). Higher BMI and male sex seemed to be associated with increased symptom severity, but this finding was not significant in our relatively small sample.

Increased nasal viral load was also associated with increasing symptom severity, with median values of 4.1, 4.8, and 6.9 log copies/mL in asymptomatic/mild, moderate, and severe cases, respectively (Fig S1A). There was a trend towards higher anti-RBD Ig levels at day 28 among those with more severe illness, though this finding did not reach statistical significance (Table 1, Fig S1B).

**Table 1: Participant characteristics by symptom severity**

	Asymptomatic or Mild (n=66)	Moderate (n=68)	Severe (n=9)	P value
Age (mean years)	31.4	32.7	53.7	<b>0.003</b>
Female (n)	37/66 (56%)	32/68 (47%)	4/9 (44%)	0.53
BMI (mean, adults only)	29.3	29.8	34.2	0.39
Cardiovascular disease present* (n, adults >18 only)	11/43 (26%)	8/57 (14%)	5/9 (56%)	<b>0.02</b>
Pulmonary disease present** (n, adults >18 only)	6/43 (14.0%)	6/57 (11%)	3/9 (33%)	0.18
Maximum nasal viral load (median, log copies/mL)	4.1	4.8	6.9	<b>0.02</b>
Day 28 antibody response (median ELISA Ig OD)	2.0	1.9	2.5	0.08

\*Cardiovascular disease = coronary artery disease, hypertension, or diabetes mellitus

\*\*Pulmonary disease = asthma or history of smoking

## Viral load and antibody response

Higher nasal viral load was associated with a higher antibody response in adults, as measured by anti-RBD total Ig levels on day 28 ( $p<0.001$ ) (Fig S2A). Higher BMI and the presence of cardiovascular disease, defined as report of coronary artery disease, hypertension, or diabetes, among adults were also



232 associated with increased antibody response ( $p < 0.001$  for BMI) despite only a weak correlation between  
233 BMI and viral load (Fig S2B&C). This association of increased antibody levels in those with higher BMIs  
234 persisted even when controlling for symptom severity and the presence of cardiovascular disease  
235 ( $p = 0.001$ ). Neither viral load nor antibody response varied by age and sex.

### 237 **Symptoms and antibody titers at extended follow-up**

238 Follow-up data was obtained at a single study visit 8-10 months after enrollment, between May 5 and  
239 August 27, 2021, for 91 COVID-positive participants out of the 315 individuals enrolled in the original  
240 study cohort, including 24 children and 67 adults (Table 2). Of the 91 participants, 45% (41/91) self-  
241 rated their COVID-19 illness as having been asymptomatic or mild, compared to 46% of our original  
242 cohort that we classified as such. At the time of follow-up, 47/91 (52%) participants were now fully  
243 vaccinated.

244  
245 Fifteen participants (3 children ages 10, 12, and 15; and 12 adults), representing 16% of this follow-up  
246 cohort, reported lingering health concerns that they attributed to COVID-19, including the presence of at  
247 least one long COVID symptom suggestive of PASC (post-acute sequelae of SARS-CoV-2 infection) that  
248 had persisted since the time of their acute infection (Table 2). The most commonly reported ongoing  
249 health concerns were taste and smell not back to normal (6 participants), problems with memory (5  
250 participants), trouble sleeping (4 participants), and inability to exercise to pre-COVID levels (4  
251 participants). Additional health issues reported by at least two participants were problems with paying  
252 attention, lightheadedness, heart palpitations, feeling weak or tired 24-48 hours after activity, and an  
253 alteration of taste or smell.

254  
255 There was no relationship between the presence of ongoing symptoms suggestive of PASC reported at  
256 follow-up and vaccination status, symptom severity during acute infection ( $n = 56$ ), age, sex, BMI, or  
257 maximum viral load during acute infection ( $n = 56$ ). However, participants who reported symptoms  
258 suggestive of PASC had a higher antibody level on day 28 of their acute infection compared to those who  
259 did not report any lingering health concerns related to their COVID illness (median ELISA OD 2.3 (95% CI  
260 2.2-2.6) vs. 1.9 (95% CI 1.3-2.2) in PASC and non-PASC individuals, respectively,  $p = 0.006$ ) (Fig 3). Of  
261 those with ELISA OD  $\geq 2.0$  at day 28, 26% (9/34) went on to report symptoms of PASC, compared to 7%  
262 (3/41) of those with ELISA OD  $< 2.0$  at day 28 ( $p = 0.02$ ).

263  
264 **Fig 3. Antibody data at D28 by post-acute sequelae of SARS-CoV-2 (PASC) at 8-10 months.**

265 91 study participants completed an extended follow up visit, of which 15 individuals reported at  
 266 least one symptom consistent with PASC. Black and red denote vaccinated and unvaccinated  
 267 people respectively; red triangles are specifically indicate antibody negative at follow-up. The  
 268 antibody titers at D28 for 12 of these individuals were significantly higher than for individuals  
 269 with no persisting symptoms (median ELISA OD 2.3 (95% CI 2.2-2.6) vs. 1.91 (95% CI 1.3-2.2) in  
 270 PASC and non-PASC individuals, respectively,  $p=0.006$ ). Titers were missing for the other 3  
 271 individuals.

272  
 273 As expected, all those who reported a history of vaccination had detectable antibody levels at follow-up.  
 274 Among 26 participants (9 index cases and 17 household contacts) who remained unvaccinated at the 8-  
 275 10 month follow-up, 19 (73%) also had detectable antibodies. In this small sample, there was no  
 276 difference in symptom severity, age, sex, BMI, maximum viral load during acute infection, and antibody  
 277 response at day 28 between antibody-positive and antibody-negative unvaccinated individuals at the 8-  
 278 10 month extended visit.

279  
 280 **Table 2: Participant characteristics at extended follow-up, occurring a median of 8 months (IQR 8-  
 281 10) after initial enrollment.**

Participant characteristics	Total N=91
	Index cases (n=33) Household cases (n=58)
Male	38 (42%)
Age	
>18	67 (74%)
12-18	16 (17%)
<12	8 (8%)
Median age (IQR)	29 (IQR 17-48)
Self-rated symptom severity during acute illness	
Asymptomatic	9 (10%)
Mild	32 (35%)
Moderate	42 (46%)
Hospitalized	3 (3%)
Unknown	5 (5%)
Long COVID/PASC (persistent symptoms lasting >6 months)	15 (16%)
Trouble sleeping	4/15 (27%)

Problems with memory	5/15 (33%)
Problems with paying attention	3/15 (20%)
Problems with feeling lightheaded	2/15 (13%)
Periods of racing heart rate	3/15 (20%)
Inability to exercise at pre-COVID level	4/15 (27%)
Inability to return to usual pre-COVID activities	1/15 (7%)
Feeling weak/tired 24-48 hours after activity	3/15 (20%)
Taste and smell not back to normal*	6/15 (40%)
Problems with appetite	0/15 (0%)
Inability to return to work or school	0/15 (0%)
Vaccinated at D180 visit**	59 (65%)
Full	47/59 (80%)
Moderna (partial or full)	22/59 (37%)
Pfizer (partial or full)	33/59 (56%)
Johnson & Johnson (full)	4/59 (7%)
Unvaccinated at D180 visit	31 (34%)
Age <18	16/31 (51%)
Age 12-18	7/31 (23%)
Age <12	8/31 (26%)

\*Not specifically elicited but reported as frequent ongoing symptom

\*\*One participant was unaware of their vaccination status because they had participated in a blinded vaccine research study

## Discussion

We integrate symptom, viral load, and antibody levels from a sizable and diverse outpatient cohort that underwent daily symptom follow-up during the first six months of the SARS-CoV-2 epidemic in the US, as well as a single long-term follow-up for PASC. Household-based recruitment after enrollment of a symptomatic index case allowed for active surveillance and analysis of SARS-CoV-2 symptoms in 143 participants through the early phase of illness, before the development of antibodies. The bulk of participants (121/143, 85%) had mild or moderate disease. Interestingly, 16% of household contacts were truly asymptomatic, confirmed by daily prospective follow-up through 21 days. This differs from studies on other outpatient cohorts from 2020, which found that most or all patients were pre-symptomatic and not truly asymptomatic [10–12]. This may be attributable to the small size and heterogeneity of populations studied (including residents of long-term skilled nursing facilities) and/or

297 slight differences in symptom ascertainment and scoring, as we still considered participants  
298 asymptomatic if they reported one cumulative symptom for the duration of their enrollment, as long the  
299 symptom reported was not anosmia, dyspnea, or new or worsening cough.

300  
301 A study conducted in two hospitals in Hong Kong found that in patients with severe/critical or moderate  
302 disease, viral loads in respiratory tract samples peaked in the second week of illness, whereas it peaked  
303 in the first week of illness among patients with mild/moderate disease [13]. Our data complements this  
304 finding, as patients with more severe disease or requiring hospitalization had symptoms peak around day  
305 9, as opposed to individuals with milder or moderate disease whose symptoms peaked only 3 to 4 days  
306 after symptom onset. Time to peak illness of symptoms is not often reported in the research literature  
307 but is important for counseling patients. A Canadian study that employed remote monitoring of those  
308 quarantining at home found that symptoms peaked 1-2 days later in older people compared to younger  
309 persons [14]. Overall, symptoms early in the pandemic were reported to last a median of 2-3 weeks  
310 [15,16], though often persisting as long as 3-5 weeks [16–18].

311  
312 Consistent with other outpatient studies, we found that greater disease severity (more cumulative  
313 symptoms) was associated with increased age [10,16,19–21] and the presence of cardiovascular disease  
314 (defined as coronary artery disease, hypertension, or diabetes mellitus in our study) [16,21–23]. We also  
315 saw nonsignificant trends towards greater disease severity in males and those with higher BMI. Other,  
316 but not all, studies have borne out these associations [16,19–22], likely reflecting unmeasured  
317 heterogeneity in populations. Overall, the symptom data reported here can serve as a comparative  
318 baseline for understanding how symptoms evolved with the evolution of different SARS-CoV-2 variants  
319 alongside evolving immunity in the US population.

320  
321 Unlike most other outpatient cohort studies conducted early in the pandemic in the United States, we  
322 integrated viral load and antibody response data alongside information collected from daily symptom  
323 diaries. This revealed an association between symptom severity and increased viral loads, supporting a  
324 well-established body of evidence from animal models and clinical studies that viral load is a likely  
325 determinant of COVID-19 disease severity [23]. Early studies conducted largely in hospitalized patients  
326 assessing antibody kinetics showed higher antibody levels in those with more severe disease and higher  
327 viral loads [24–27]. In this cohort dominated by non-severe disease, we observed a similar, albeit  
328 nonsignificant, trend with increased antibody response with higher viral load in the small group with  
329 severe disease (n=9) but no detectable difference between those categorized as having mild or moderate

disease. Most, but not all, subsequent studies in diverse community cohorts have confirmed weaker antibody responses in non-hospitalized patients, along with higher neutralizing antibodies in those with severe disease [28–31].

Interestingly, we found that increased BMI was strongly correlated with a higher antibody response in our cohort, seemingly independent of disease severity. Several prior studies have found the same, alongside evidence of over-reactive immune response in obese patients [32–34]. However, there is discordance in the literature since not all could adjust for symptom severity, and some described reduced immune responses in obese patients [35]. In addition to mechanistic studies, further analysis of large non-hospitalized cohorts, also including younger obese patients [36], may shed more light on this question.

Out of 91 COVID-positive patients from the parent study, 15 (16%) individuals noted persistent symptoms attributable to PASC. Like prior data evaluating PASC, many lingering symptoms our patients reported were neurological, such as forgetfulness and sleep disturbances, as well as related to exercise intolerance [37]. Detecting predictive markers for long COVID syndrome has been an important research priority given the millions affected by PASC. In our small sample, we found that a significantly higher proportion of people with ELISA OD  $\geq 2.0$  at day 28 reported symptoms of PASC at 8-10 months compared to those with ELISA OD  $< 2.0$ . This aligns with an association of symptom severity in the acute phase of infection and subsequent PASC described in the STOP-COVID registry, which followed a large outpatient cohort from 2020 in the United States [22]. Large multi-omics and immunologic profiling studies that have sought to find an acute immunological marker of PASC in hospitalized patient populations have highlighted the potential importance of specific autoantibodies in aberrant pathophysiology leading to subsequent long COVID phenotypes [38–40]. Our findings indicate that the potential clinical utility of assessing acute humoral response as a predictor for PASC is not limited to hospitalized patients and should continue to be evaluated in later SARS-CoV-2 variants.

This data was collected before the availability of vaccines or outpatient therapies directed against COVID-19 and thus represents symptoms and disease course in the absence of modifying interventions. It is necessarily limited in its characterization of the earliest D614G SARS-CoV-2 strain that swept the United States in 2020, before the emergence of new COVID-19 variants. Unlike subsequent studies with daily sampling, sampling for nasal viral loads occurred weekly, while antibody responses were measured at study enrollment and 28 days later. Thus the study was limited in its capture of peak measurements and

363 associated viral load and antibody kinetics afforded by more frequent sampling. Although symptom data  
364 relied on patient self-report, daily online questionnaires likely minimized recall bias. Regarding detection  
365 of PASC, extended follow-up visits were carried out before more formal or comprehensive definitions of  
366 PASC were proposed [41] and did not involve in-depth clinical evaluation. Thus, prevalence of PASC may  
367 be underestimated or imprecise, limiting investigation of factors associated with PASC. Another  
368 limitation is

369  
370 In conclusion, this study contributes to an understanding of the full spectrum of illness caused by SARS-  
371 CoV-2 at different stages in the pandemic, providing early baseline data that can help assess changes in  
372 virulence and patterns of disease in the context of evolving variants, stages of vaccination, and increasing  
373 availability of treatment for non-hospitalized illness. A significant proportion of participants reported  
374 symptoms consistent with PASC, underlying the common occurrence of long COVID symptoms in even  
375 mild/moderate illness and the need for further study in these populations. Stored specimens from our  
376 study may contribute to such ongoing research [42].

## 377 **Acknowledgements**

378 We thank our wonderful CO-HOST study participants, Moby and the Chapel Hill CRS, and the UNC RDC  
379 team. Thanks to Michelle Berrey, JoAnn Kuruc, and Dania Munson for help with protocol writing and  
380 submission; to Oksana Kharabora, Maureen Furlong, Amy James Loftis, and Dana Swilley for help with  
381 study preparation and implementation.

## 382 **References**

- 383  
384  
385 1. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in  
386 posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-  
387 CoV-2: an observational cohort study. *Lancet Infect Dis.* 2020;20: 565–574.
- 388 2. Suh HJ, Kim DH, Heo EY, Lee HW, Lee JK, Lee CS, et al. Clinical characteristics of COVID-19: Clinical  
389 dynamics of mild severe acute respiratory syndrome Coronavirus 2 infection detected by early  
390 active surveillance. *J Korean Med Sci.* 2020;35: e297.
- 391 3. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG  
392 responses in COVID-19 patients. *Emerg Microbes Infect.* 2020;9: 940–948.
- 393 4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019  
394 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for



- 395 Disease Control and Prevention. JAMA. 2020;323: 1239–1242.
- 396 5. Cerami C, Rapp T, Lin F-C, Tompkins K, Basham C, Muller MS, et al. High household transmission of  
397 SARS-CoV-2 in the United States: living density, viral load, and disproportionate impact on  
398 communities of color. medRxiv. 2021. doi:10.1101/2021.03.10.21253173
- 399 6. Centers for Disease Control and Prevention. CDC 2019–Novel Coronavirus (2019-nCoV) Real-Time  
400 RT-PCR Diagnostic Panel. In: CDC 2019–Novel Coronavirus (2019-nCoV) Real-Time RT-PCR  
401 Diagnostic Panel [Internet]. Available: <https://www.fda.gov/media/134922/download>
- 402 7. Muller MS, Chhetri SB, Basham C, Rapp T, Lin F-C, Lin K, et al. Practical strategies for SARS-CoV-2 RT-  
403 PCR testing in resource-constrained settings. *Diagn Microbiol Infect Dis*. 2021;101: 115469.
- 404 8. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The receptor  
405 binding domain of the viral spike protein is an immunodominant and highly specific target of  
406 antibodies in SARS-CoV-2 patients. *Sci Immunol*. 2020;5. doi:10.1126/sciimmunol.abc8413
- 407 9. Coronavirus Disease 2019 (COVID-19) 2020 interim case definition, approved august 5, 2020. 15  
408 Aug 2022 [cited 28 Aug 2024]. Available: [https://ndc.services.cdc.gov/case-definitions/coronavirus-](https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020-08-05/)  
409 [disease-2019-2020-08-05/](https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020-08-05/)
- 410 10. Yousaf AR, Duca LM, Chu V, Reses HE, Fajans M, Rabold EM, et al. A prospective cohort study in non-  
411 hospitalized household contacts with SARS-CoV-2 infection: symptom profiles and symptom change  
412 over time. *Clin Infect Dis*. 2020. doi:10.1093/cid/ciaa1072
- 413 11. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and  
414 Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility -  
415 King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69: 377–381.
- 416 12. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2  
417 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*. 2020;382: 2081–2090.
- 418 13. Lui G, Ling L, Lai CK, Tso EY, Fung KS, Chan V, et al. Viral dynamics of SARS-CoV-2 across a spectrum  
419 of disease severity in COVID-19. *J Infect*. 2020;81: 318–356.
- 420 14. Gershon AS, Patel N, Liaqat S, Liaqat D, de Lara E, To T, et al. Symptom Burden in Patients of Different  
421 Ages with Acute COVID-19 Infection Quarantining at Home. B57 CUTTING EDGE COVID RESEARCH.  
422 American Thoracic Society; 2022. pp. A3170–A3170.
- 423 15. Lane A, Hunter K, Lee EL, Hyman D, Bross P, Alabd A, et al. Clinical characteristics and symptom  
424 duration among outpatients with COVID-19. *Am J Infect Control*. 2022;50: 383–389.
- 425 16. Blair PW, Brown DM, Jang M, Antar AAR, Keruly JC, Bachu VS, et al. The Clinical Course of COVID-19  
426 in the Outpatient Setting: A Prospective Cohort Study. *Open Forum Infect Dis*. 2021;8: ofab007.
- 427 17. Cellai M, O’Keefe JB. Characterization of Prolonged COVID-19 Symptoms in an Outpatient



- 428 Telemedicine Clinic. *Open Forum Infect Dis.* 2020;7: ofaa420.
- 429 18. Tenforde MW, Billig Rose E, Lindsell CJ, Shapiro NI, Files DC, Gibbs KW, et al. Characteristics of Adult  
430 Outpatients and Inpatients with COVID-19 - 11 Academic Medical Centers, United States, March-May  
431 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69: 841–846.
- 432 19. Nguyen NT, Chinn J, Kirby K, Hohmann SF, Amin A. Outcomes of COVID-19 adults managed in an  
433 outpatient versus hospital setting. *PLoS One.* 2022;17: e0263813.
- 434 20. Pettrone K, Burnett E, Link-Gelles R, Haight SC, Schrodt C, England L, et al. Characteristics and Risk  
435 Factors of Hospitalized and Nonhospitalized COVID-19 Patients, Atlanta, Georgia, USA, March-April  
436 2020. *Emerg Infect Dis.* 2021;27: 1164–1168.
- 437 21. Halalau A, Odish F, Imam Z, Sharrak A, Brickner E, Lee PB, et al. Epidemiology, Clinical  
438 Characteristics, and Outcomes of a Large Cohort of COVID-19 Outpatients in Michigan. *Int J Gen Med.*  
439 2021;14: 1555–1563.
- 440 22. Pływaczewska-Jakubowska M, Chudzik M, Babicki M, Kapusta J, Jankowski P. Lifestyle, course of  
441 COVID-19, and risk of Long-COVID in non-hospitalized patients. *Front Med.* 2022;9: 1036556.
- 442 23. da Silva SJR, de Lima SC, da Silva RC, Kohl A, Pena L. Viral Load in COVID-19 Patients: Implications  
443 for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. *Front Med.*  
444 2021;8: 836826.
- 445 24. Zhang X, Lu S, Li H, Wang Y, Lu Z, Liu Z, et al. Viral and antibody kinetics of COVID-19 patients with  
446 different disease severities in acute and convalescent phases: A 6-month follow-up study. *Virol Sin.*  
447 2020;35: 820–829.
- 448 25. Masiá M, Telenti G, Fernández M, García JA, Agulló V, Padilla S, et al. SARS-CoV-2 Seroconversion and  
449 Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response.  
450 *Open Forum Infect Dis.* 2021;8: ofab005.
- 451 26. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in  
452 relation to COVID-19 severity. *J Clin Invest.* 2020;130: 5235–5244.
- 453 27. Li L, Liang Y, Hu F, Yan H, Li Y, Xie Z, et al. Molecular and serological characterization of SARS-CoV-2  
454 infection among COVID-19 patients. *Virology.* 2020;551: 26–35.
- 455 28. Sancilio A, Schrock JM, Demonbreun AR, D'Aquila RT, Mustanski B, Vaught LA, et al. COVID-19  
456 symptom severity predicts neutralizing antibody activity in a community-based serological study. *Sci*  
457 *Rep.* 2022;12: 12269.
- 458 29. Horton DB, Barrett ES, Roy J, Gennaro ML, Andrews T, Greenberg P, et al. Determinants and  
459 Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective  
460 Cohort Study. *J Infect Dis.* 2021;224: 1345–1356.

- 461 30. Imai K, Kitagawa Y, Tabata S, Kubota K, Nagura-Ikeda M, Matsuoka M, et al. Antibody response  
462 patterns in COVID-19 patients with different levels of disease severity in Japan. *J Med Virol*. 2021;93:  
463 3211–3218.
- 464 31. Hung IF-N, Cheng VC-C, Li X, Tam AR, Hung DL-L, Chiu KH-Y, et al. SARS-CoV-2 shedding and  
465 seroconversion among passengers quarantined after disembarking a cruise ship: a case series.  
466 *Lancet Infect Dis*. 2020;20: 1051–1060.
- 467 32. Onyango TB, Zhou F, Bredholt G, Brokstad KA, Lartey S, Mohn KG-I, et al. SARS-CoV-2 specific  
468 immune responses in overweight and obese COVID-19 patients. *Front Immunol*. 2023;14: 1287388.
- 469 33. Zhai B, Clarke K, Bauer DL, Moehling Geffel KK, Kupul S, Schratz LJ, et al. SARS-CoV-2 Antibody  
470 Response Is Associated with Age and Body Mass Index in Convalescent Outpatients. *J Immunol*.  
471 2022;208: 1711–1718.
- 472 34. Soffer S, Glicksberg BS, Zimlichman E, Efros O, Levin MA, Freeman R, et al. The Association Between  
473 Obesity and Peak Antibody Titer Response in COVID-19 Infection. *Obesity* . 2021.  
474 doi:10.1002/oby.23208
- 475 35. Tong MZ, Sng JD, Carney M, Cooper L, Brown S, Lineburg KE, et al. Elevated BMI reduces the humoral  
476 response to SARS-CoV-2 infection. *Clin Transl Immunology*. 2023;12: e1476.
- 477 36. Nilles EJ, Siddiqui SM, Fischinger S, Bartsch YC, de St Aubin M, Zhou G, et al. Epidemiological and  
478 Immunological Features of Obesity and SARS-CoV-2. *Viruses*. 2021;13. doi:10.3390/v13112235
- 479 37. Robineau O, Zins M, Touvier M, Wiernik E, Lemogne C, de Lamballerie X, et al. Long-lasting  
480 symptoms after an acute COVID-19 infection and factors associated with their resolution. *JAMA Netw*  
481 *Open*. 2022;5: e2240985.
- 482 38. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute  
483 COVID-19 sequelae. *Cell*. 2022;185: 881–895.e20.
- 484 39. Ozonoff A, Jayavelu ND, Liu S, Melamed E, Milliren CE, Qi J, et al. Features of acute COVID-19  
485 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study. *Nat*  
486 *Commun*. 2024;15: 216.
- 487 40. Leung JM, Wu MJ, Kheradpour P, Chen C, Drake KA, Tong G, et al. Early immune factors associated  
488 with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-  
489 hospitalized individuals. *Front Immunol*. 2024;15: 1348041.
- 490 41. Ely EW, Brown LM, Fineberg HV, National Academies of Sciences, Engineering, and Medicine  
491 Committee on Examining the Working Definition for Long Covid. Long covid defined. *N Engl J Med*.  
492 2024 [cited 29 Sep 2024]. doi:10.1056/NEJMs2408466
- 493 42. Figueiredo JC, Hirsch FR, Kushi LH, Nembhard WN, Crawford JM, Mantis N, et al. Mission,

494 Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet)

495 Epidemiologic Cohort Studies. Open Forum Infect Dis. 2022;9: ofac171.

496

## 497 **Supporting Information Captions**

498 **Fig S1. Comparison of symptom severity, viral load, and antibody response.**


499

500 **Fig S2. Comparison of antibody response, viral load, and BMI.**



501 Comparison of ELISA OD value on study day 28 and maximum viral load measured by PCR testing

502 (A) and BMI of adults (B) as well as comparison of maximum viral load and BMI of adults (C).

503




Figure

**A****B**

Figure

# ELISA Titer D28



Figure